Fenwick represented KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need, in its upsized public offering of 6.1 million shares of common stock at a price of $36 per share, with gross proceeds of approximately $222.5 million.
Jefferies LLC; Stifel, Nicolaus & Company, Incorporated; and Cantor Fitzgerald & Co. acted as the joint book-running managers for the offering. Needham & Company and Roth Capital Partners acted as co-managers.
More information about the offering can be obtained from KalVista's announcement.
The Fenwick transaction team included corporate partners Robert Freedman and Julia Forbess and associates Steven Jean, Emily Yi and David Heckman.